<br>抗氧化剂和抗 VEGF 的协同治疗：安全有效地消除角膜新生血管,Advanced Healthcare Materials

当前位置： X-MOL 学术 › Adv. Healthcare Mater. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

抗氧化剂和抗 VEGF 的协同治疗：安全有效地消除角膜新生血管
Advanced Healthcare Materials ( IF 10.0 ) Pub Date : 2023-11-29 , DOI: 10.1002/adhm.202302192
Huimin Zhu ₁ , Jinfa Ye ₁ , Yiming Wu ₁ , Yuhang Cheng ₁ , Min Su ₂ , Qixuan Dai ₃ , Yun Han ₁ , Jintao Pan ₃ , Zhenyu Wu ₂ , Chuan Chen ₂ , Chenyue Qiu ₁ , Wei Li ₁ , Gang Liu _{3,

4} , Chengchao Chu _{1,

4}

Affiliation

角膜新生血管（CNV）是世界上导致失明的主要原因之一。在临床实践中；然而，实现无创且安全的治疗仍然是一个挑战。在此，通过表没食子儿茶素没食子酸酯/没食子酸和Cu(II)的共组装制备了具有优异抗氧化和抗血管活性的生物相容性壳。在内部加载葡萄糖氧化酶 (GO x ) 后，用二聚体 DPA-Zn 修饰外壳，以共同传递血管内皮生长因子 (VEGF) 小干扰 RNA (VEGF-siRNA)。同时，精氨酸-甘氨酸-天冬氨酸肽（RGD）肽工程细胞膜涂层可改善血管生成靶向性，并且与多功能纳米药物（CEGs/RGD）具有生物相容性。滴眼液给药后，CEGs/RGD 的目标是富集新血管形成，CEGs NPs 进入细胞。然后，内部GO x消耗葡萄糖，局部pH值降低，进而导致EGCE和VEGF-siRNA的释放。因此，纳米药物通过下调分化簇 31 和 VEGF 的抗氧化和抗血管协同作用，显着减少血管生成并抑制 CNV 形成。纳米药物通过抗氧化剂/基因的联合作用代表了一种安全、高效的CNV治疗方法，具有重要的理论和临床意义。

"点击查看英文标题和摘要"

A Synergistic Therapy With Antioxidant and Anti-VEGF: Toward its Safe and Effective Elimination for Corneal Neovascularization

Corneal neovascularization (CNV) is one of the leading causes of blindness in the world. In clinical practice; however, it remains a challenge to achieve a noninvasive and safe treatment. Herein, a biocompatible shell with excellent antioxidant and antivascularity is prepared by co-assembly of epigallocatechin gallate/gallic acid and Cu (II). After loading glucose oxidase (GOx) inside, the shell is modified with dimeric DPA-Zn for codelivering vascular endothelial growth factor (VEGF) small interfering RNA (VEGF-siRNA). Meanwhile, the Arg-Gly-Asp peptide (RGD) peptide-engineered cell membranes coating improves angiogenesis-targeting and is biocompatible for the multifunctional nanomedicine (CEGs/RGD). After eye drops administration, CEGs/RGD targets enrichment in neovascularization and CEGs NPs enter cells. Then, the inner GOx consumes glucose with a decrease in local pH, which in turn leads to the release of EGCE and VEGF-siRNA. As a result, the nanomedicines significantly reduce angiogenesis and inhibit CNV formation through synergistic effect of antioxidant and antivascular via down-regulation of cluster of differentiation 31 and VEGF. The nanomedicine represents a safe and efficient CNV treatment through the combined effect of antioxidant/gene, which provides important theoretical and clinical significance.

更新日期：2023-11-29

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南